Tue.Aug 30, 2022

article thumbnail

The futility of banner ads

World of DTC Marketing

Digital ad spending in the industry will reach $15.84 billion in 2022. Although growth in digital budgets is slowing, we estimate the category will see nearly $20 billion in spending in 2024. For every $1 million invested in online banner ads, just 0.1%, or $1,000, derives value for brands, resulting in $999,000 wasted by brands. So why is pharma wasting so much money?

Branding 270
article thumbnail

Jounce’s latest setback dampens outlook for another cancer immunotherapy target

Bio Pharma Dive

The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.

Medicine 169
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA accepts Sanofi’s haemophilia A treatment BLA for priority review

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has accepted Sanofi ’s efanesoctocog alfa (BIVV001) Biologics License Application (BLA), to treat haemophilia A, for priority review. A decision from the regulatory agency on approval for the therapy is anticipated on 28 February next year. The application is based on findings from the open-label, non-randomised, interventional Phase III XTEND-1 clinical trial designed to evaluate the safety, efficacy and pharmacokinetics of efanesoctocog alfa given once

Trials 130
article thumbnail

Neurocrine, with latest deal, gets a foothold in Europe

Bio Pharma Dive

The neuroscience-focused company has agreed to buy U.K.-based Diurnal for around $57 million, a move it expects to “accelerate the establishment of its clinical development and commercial activities” in Europe.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Testing Facility Called “Game Changer” in Regenerative Medicine

Pharma Mirror

The RegeneratOR Test Bed is an exciting game changer. The testing facility, located in North Carolina, provides supportive technology at no cost allowing companies to test and prove their cell-based products at various stages of development. The Test Bed utilizes Cytocentric principles, an innovative philosophy of putting the needs of the vulnerable cells front and center while growing and manipulating them in vitro.

Medicine 130
article thumbnail

IN-FOCUS: Verista

Pharmaceutical Technology

RANKINGS 2022 Excellence Business Expansion Commended Excellence Innovation Commended Excellence Investments Commended. The Verdict. Verista is a Life Sciences business, technology and compliance firm specializing in systems, quality, and validation solutions throughout the product lifecycle. The company has been ranked in the 2022 Excellence Rankings in the areas of Business Expansion , Innovation and Investments.

More Trending

article thumbnail

Moderna’s omicron-targeting Covid-19 booster gets Swissmedic approval

Pharmaceutical Technology

Moderna has obtaine d temporary authorisation from Swissmedic for its Omicron-targeting bivalent booster vaccine for Covid-19, Spikevax Bivalent Original/Omicron (mRNA-1273.214), for individuals aged 18 years and above. . The vaccine is indicated for active immunisation for the prevention of Covid-19. It comprises 25µg mRNA-1273 (Spikevax) and 25µg of a vaccine candidate that acts on the Omicron variant of concern (BA.1).

article thumbnail

U.S. life expectancy drops sharply, the second consecutive decline

STAT News

Americans born in 2021 can expect to live for just 76.1 years — the lowest life expectancy has been since 1996, according to a new government analysis published Wednesday. This is the biggest two-year decline — 2.7 years in total — in almost 100 years. The Covid-19 pandemic is the primary cause of the decline. However, increases in the number of people dying from overdoses and accidents is also a significant factor.

Research 145
article thumbnail

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs. The finished product dosage form, clinical development and the final products’ marketing and sales across the globe will be handled by Insud. .

article thumbnail

10 key questions about monkeypox the world needs to answer

STAT News

Just over three months ago, public health authorities in the U.K., Europe, and the U.S. began to sound the alarm on the arrival of monkeypox. Since then, this long-neglected tropical disease — which until this year was mostly limited to periodic spillovers in the areas of Western and Central Africa where the virus is endemic — has gone global.

Scientist 142
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

August 30, 2022: FDA Announces Webinar on Patient-Focused Drug Development Draft Guidance

Rethinking Clinical Trials

The US Food and Drug Administration (FDA) will host a webinar on September 9 for industry, patient groups, and other interested stakeholders to discuss and answer questions about the draft guidance, Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The draft guidance, known as “Guidance 3,” is the third of 4 methodological guidance documents for patient-focused drug development that describe how patients, caregivers, r

article thumbnail

Marijuana use is outpacing cigarette use for the first time on record

NPR Health - Shots

Cigarette use has been declining for decades, while marijuana use has been on the rise, according to a new Gallup survey in the U.S.

135
135
article thumbnail

AstraZeneca gains first approval for Evusheld as COVID-19 treatment

BioPharma Reporter

AstraZeneca's long-acting antibody combination Evusheld has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection: marking the first global marketing approval of Evusheld as a treatment for COVID-19.

Antibody 105
article thumbnail

Opinion: ‘Whose life do I prioritize?’ A choice no parent wants to make

STAT News

When an obstetrician or midwife cuts the umbilical cord after a child is born, the room is filled with tense silence until the baby’s first cry is heard. I once heard this silence in an operating room where 32 people were bustling around, all awaiting the birth of a baby with a massive growth covering her neck and jaw that might make it difficult — if not impossible — for her to breathe on her own.

105
105
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Neurocrine Bio agrees $57m takeover of UK biotech Diurnal

pharmaphorum

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. The 27.5 pence-a-share cash deal values Diurnal at around £48.3 million ($57 million), a 144% premium to the biotech’s closing share price on Friday.

article thumbnail

Unprecedented! Incredible! Scientific grant applications are getting heavier on hype

STAT News

“N ovel.” “Exciting.” “Incredible.” “Devastating.” “Unprecedented.” You name the adjective, and a scientist has probably stuck it into a grant application to score funding. In semi-official scientific parlance, they’re known as “hype.” And adjectives like these are becoming more common in grant applications, according to a new study.

Scientist 105
article thumbnail

FDA expected to authorize new omicron-specific COVID boosters this week

NPR Health - Shots

The Food and Drug Administration is planning to authorize a new generation of COVID-19 boosters this week that for the first time will target the omicron variant. (Image credit: FREDERIC J.

Drugs 98
article thumbnail

Opinion: Five years after Kymriah: Ensuring the next cell and gene therapies reach patients

STAT News

Five years ago today , the Food and Drug Administration issued a landmark approval for Kymriah, the first gene therapy available in the United States. Cell and gene therapy products can transform how certain diseases are treated, offering life-extending and potentially curative benefits for patients living with life-threatening or debilitating diseases.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

What to expect from Advanced Therapies Europe 2022

Drug Discovery World

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. The event is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market.

article thumbnail

Surprise billing legal limbo & device price persuasion

STAT News

You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow of money through the health care system.  Sign up here  to get it in your inbox. A different way for physicians to get recertified. Doctors dislike renewing their specialty certifications, also known as “maintenance of certification” in industry jargon.

Doctors 98
article thumbnail

5 Tips for Crafting Successful Webinar Survey Questions (Examples Included)

XTalks

When you’re planning a webinar, one of the most important things to do is create a survey for attendees to partake in. This survey will help you gather information about your audience and their needs. In order to create an effective survey, you need to ask the right questions. We will discuss five tips for crafting successful webinar survey questions!

article thumbnail

A grand test of the Apple Watch in health & a giant leap for data access

STAT News

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences.  Sign up to get this newsletter  delivered in your inbox every Tuesday and Thursday.  A giant leap for data access?

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

ESC22: Despite trial misses, Bayer preps phase 3 for asundexian

pharmaphorum

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial programme will investigate the potential of asundexian in up to 30,000 patients with atrial fibrillation (AF) as well as patients with a non-cardioembolic ischaemic stroke or high-risk transient ischemic attack (TIA), said Bayer.

Trials 94
article thumbnail

Potential Food IPOs to Look Out For in 2022

XTalks

An initial public offering (IPO) refers to the process of offering shares of a private corporation to the public in a new stock issuance for the first time, allowing a company to raise equity capital from public investors. Meanwhile, it also allows public investors to participate in the offering. Food IPOs offer exciting opportunities for investors, with 2021 seeing the likes of Oatly and Krispy Kreme go public.

article thumbnail

European Commission approves pharma trio’s Ranivisio

Pharma Times

Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union

118
118
article thumbnail

Applied StemCell expands manufacturing facility to support cell and gene therapies

BioPharma Reporter

Applied StemCell is expanding its cGMP facility to increase its cell banking and cell product manufacturing capacity.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

EnACT patient-centric design in digital health development

pharmaphorum

New practical guide walks digital health entrepreneurs through the patient and public involvement and engagement process. . Digital transformation could revolutionise healthcare, making for happier, healthier populations – but only if solutions are designed and deployed with patients at the heart. . That’s why a newly published, evidence-based guide for digital innovators, from the Academic Health Science Networks (AHSN) Network, the University of Plymouth, and Boehringer Ingelheim, aims to s

article thumbnail

Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia

Pharma Times

It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe

109
109
article thumbnail

Thermo Fisher expands US viral vector manufacturing capabilities

BioPharma Reporter

Thermo Fisher Scientific has opened its new viral vector manufacturing facility in Plainville, Massachusetts.

article thumbnail

The FDA is expected to authorize a new COVID booster that targets omicron

NPR Health - Shots

The Food and Drug Administration is planning to authorize a new generation of COVID-19 boosters this week that for the first time will target the omicron variant.

Drugs 76
article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.